Format

Send to

Choose Destination
See comment in PubMed Commons below
Bone Marrow Transplant. 2014 May;49(5):671-8. doi: 10.1038/bmt.2014.4. Epub 2014 Feb 10.

Matched unrelated donor allogeneic transplantation provides comparable long-term outcome to HLA-identical sibling transplantation in relapsed diffuse large B-cell lymphoma.

Author information

1
Department of Hematology & Bone Marrow Transplantation, Ramban Medical Center, Haifa, Israel.
2
Clinical Hematology Division, Hospital de la Santa Creu i Sant Pau, Barcelona, Spain.
3
Clinical Hematology, Hopital Pitie Salpetriere, Paris, France.
4
Abteilung Hematologie und Onkologie, Universitätsklinikum Göttingen, Gottingen, Germany.
5
Department of Hematology & Bone Marrow Transplantation, Chaim Sheba Medical Center, Tel-Hashomer, Israel.
6
Service Hematologie Adulte, Hôpital Necker, Paris, France.
7
Department of Haematology, University Medical Centre, Utrecht, The Netherlands.
8
Service de Maladies du Sang, Hopital Claude Huriez, Lille, France.
9
Centre for Clinical Haematology, Queen Elizabeth Hospital, Birmingham, UK.
10
Department of Hematology, Radboud University-Nijmegen Medical Centre, Nijmegen, The Netherlands.
11
Division of Hematology, Oncology and Hemostasiology, University Hospital Leipzig, Leipzig, Germany.
12
Department of Haematology, University College London Hospital, London, UK.
13
Unit de Transplantation et de Therapie Cellulaire, Institut Paoli Calmettes, Marseille, France.
14
CHU Dept. Hematologie, Hopital de Purpan, Toulouse, France.
15
BMT Unit, Department of Internal Medicine, University of Saarland, Saarbrucken, Germany.
16
Department of Hematology, University Hospital, Basel, Switzerland.
17
Department of Hematology, Nottingham City Hospital, Nottingham, UK.
18
Medizinische Klinik u. Poliklinik V, University of Heidelberg, Heidelberg, Germany.
19
Department of Haematology, Addenbrookes Hospital, Cambridge University, Cambridge, UK.

Abstract

The objective of this retrospective analysis was to compare outcomes of patients with diffuse large B-cell lymphoma (DLBCL) who received either a matched sibling (sib) or an unrelated donor (URD) allogeneic hematopoietic cell transplantation (allo-HCT). Long-term outcome of 172 DLBCL patients receiving URD-HCT between 2000 and 2007 and reported to the European Group for Blood and Marrow Transplantation, was compared with that of 301 subjects, allografted from sib-HCT. With a median follow-up of 45 months, 3-year PFS approached 35% for both groups; overall survival (OS) was 42% for sib-HCT versus 37% for URD (NS). Multivariate analyses confirmed that donor type was not associated with differences in non-relapse mortality (NRM), relapse rate (RR), PFS or OS. Poor performance status (PS) and refractory disease adversely affected PFS and OS. Prior auto-SCT and multiple previous therapies predicted for shorter PFS. NRM was adversely affected by older age (⩾50 years), poor PS and refractory disease, and RR by time from diagnosis to allo-HCT of <36 months, prior auto-SCT, refractory disease, poor PS and in vivo T-cell depletion with alemtuzumab. This large study shows for the first time that URD-HCT is not inferior to sib-HCT, providing a reasonable therapeutic approach for DLBCL patients, having no HLA-identical sibling available.

PMID:
24510071
DOI:
10.1038/bmt.2014.4
[Indexed for MEDLINE]
PubMed Commons home

PubMed Commons

0 comments
How to join PubMed Commons

    Supplemental Content

    Full text links

    Icon for Nature Publishing Group
    Loading ...
    Support Center